Arrowhead Pharmaceuticals incurred a GAAP loss of $36.121 million in the 9 months of fiscal 2020, compared to a profit of $56.27 million in the previous year. Revenues decreased by 36% to $80,359 million compared to $125,503 million a year earlier.